• Candel Therapeutics entered an agreement November 12, 2026, to sell up to $50 million in common stock through Jefferies.
• The at-the-market program adds capacity beyond approximately $50 million already sold under the August 14, 2025, agreement.
• Jefferies will receive a 3% commission on gross proceeds, with no obligation to sell a specific share count or dollar amount.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-458522), on November 12, 2026, and is solely responsible for the information contained therein.